MARINUS PHARMACEUTICALS, INC.: 10-Q filed 2014-10-10

Name: MARINUS PHARMACEUTICALS, INC.: 10-Q filed 2014-10-10
Creator: MARINUS PHARMACEUTICALS, INC.

What MARINUS PHARMACEUTICALS, INC. reported in its quarterly report filed 2014-10-10 (fiscal Q2 2014): 25 published measures, 63 facts as tagged in accession 0001104659-14-071204.

This filing

Form: 10-Q (quarterly report)
Filed: 2014-10-10
Fiscal period: fiscal Q2 2014
Accession: 0001104659-14-071204 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MARINUS PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2014-06-30	9,478,858	USD
At 2013-12-31	11,823,945	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2014-06-30	5,003,262	USD
At 2013-12-31	2,365,770	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2014-06-30	-65,864,610	USD
At 2013-12-31	-60,382,031	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2014-06-30	8,415,735	USD
At 2013-12-31	10,037,123	USD
At 2013-06-30	13,867,698	USD
At 2012-12-31	8,633,775	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-3,322,377	USD	91
2014-01-01 to 2014-06-30	-5,557,682	USD	181
2013-04-01 to 2013-06-30	-1,681,647	USD	91
2013-01-01 to 2013-06-30	-2,651,290	USD	181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	12,044	USD	181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2014-06-30	-67,060,697	USD
At 2013-12-31	-61,503,015	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2014-06-30	11,049	USD
At 2013-12-31	16,063	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2014-01-01 to 2014-06-30	46,986	USD	181
2013-01-01 to 2013-06-30	88,482	USD	181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-3,263,019	USD	91
2014-01-01 to 2014-06-30	-5,928,234	USD	181
2013-04-01 to 2013-06-30	-1,640,799	USD	91
2013-01-01 to 2013-06-30	-2,568,201	USD	181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2014-06-30	9,448,529	USD
At 2013-12-31	11,798,502	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	29,156	USD	91
2014-01-01 to 2014-06-30	31,416	USD	181
2013-04-01 to 2013-06-30	44,498	USD	91
2013-01-01 to 2013-06-30	90,827	USD	181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2014-06-30	3,003,262	USD
At 2013-12-31	2,365,770	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2014-06-30	1,742,466	USD
At 2013-12-31	77,782	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	2,805,053	USD	91
2014-01-01 to 2014-06-30	4,953,724	USD	181
2013-04-01 to 2013-06-30	1,326,915	USD	91
2013-01-01 to 2013-06-30	2,012,416	USD	181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2014-06-30	492,064	shares
At 2013-12-31	465,029	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2014-06-30	1,195,756	USD
At 2013-12-31	1,120,680	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2014-06-30	444,842	USD
At 2013-12-31	444,842	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2014-06-30	433,793	USD
At 2013-12-31	428,779	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2014-06-30	19,280	USD
At 2013-12-31	9,380	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2014-06-30	466,454	USD
At 2013-12-31	1,096,474	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2014-06-30	100,536	USD
At 2013-12-31	1,761,379	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-4,424,683	USD	91
2014-01-01 to 2014-06-30	-7,730,671	USD	181
2013-04-01 to 2013-06-30	-2,621,721	USD	91
2013-01-01 to 2013-06-30	-4,377,325	USD	181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	457,966	USD	91
2014-01-01 to 2014-06-30	974,510	USD	181
2013-04-01 to 2013-06-30	313,884	USD	91
2013-01-01 to 2013-06-30	555,785	USD	181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2014-01-01 to 2014-06-30	5,014	USD	181
2013-01-01 to 2013-06-30	4,403	USD	181

Inspect the source

Entity: MARINUS PHARMACEUTICALS, INC. / CIK 0001267813
Captured: 2026-09-21T17:18:11.436Z
SEC response SHA-256: 1a575eff225971488326996af5ff9f0c33a97740b77d0896b473d9302ab1dfdb

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001267813.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))